Next Article in Journal
Cerebral Vascular Reactivity in Frail Older Adults with Vascular Cognitive Impairment
Next Article in Special Issue
Computer-Aided Diagnosis System of Alzheimer’s Disease Based on Multimodal Fusion: Tissue Quantification Based on the Hybrid Fuzzy-Genetic-Possibilistic Model and Discriminative Classification Based on the SVDD Model
Previous Article in Journal
Classification of Alzheimer’s Disease with and without Imagery Using Gradient Boosted Machines and ResNet-50
Open AccessReview

Biomarker-Based Signature of Alzheimer’s Disease in Pre-MCI Individuals

Center for Memory Disturbances, Lab of Clinical Neurochemistry, Section of Neurology, Department of Medicine, University of Perugia, 06132 Perugia, Italy
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Brain Sci. 2019, 9(9), 213; https://doi.org/10.3390/brainsci9090213
Received: 29 June 2019 / Revised: 10 August 2019 / Accepted: 20 August 2019 / Published: 23 August 2019
(This article belongs to the Special Issue Biomarkers for Early Diagnosis of Dementia)
Alzheimer’s disease (AD) pathology begins decades before the onset of clinical symptoms. It is recognized as a clinicobiological entity, being detectable in vivo independently of the clinical stage by means of pathophysiological biomarkers. Accordingly, neuropathological studies that were carried out on healthy elderly subjects, with or without subjective experience of cognitive decline, reported evidence of AD pathology in a high proportion of cases. At present, mild cognitive impairment (MCI) represents the only clinically diagnosed pre-dementia stage. Several attempts have been carried out to detect AD as early as possible, when subtle cognitive alterations, still not fulfilling MCI criteria, appear. Importantly, pre-MCI individuals showing the positivity of pathophysiological AD biomarkers show a risk of progression similar to MCI patients. In view of successful treatment with disease modifying agents, in a clinical setting, a timely diagnosis is mandatory. In clinical routine, biomarkers assessment should be taken into consideration whenever a subject with subtle cognitive deficits (pre-MCI), who is aware of his/her decline, requests to know the cause of such disturbances. In this review, we report the available neuropsychological and biomarkers data that characterize the pre-MCI patients, thus proposing pre-MCI as the first clinical manifestation of AD. View Full-Text
Keywords: preclinical AD; pre-MCI; biomarkers; neuropsychological assessment; neuropathological findings preclinical AD; pre-MCI; biomarkers; neuropsychological assessment; neuropathological findings
MDPI and ACS Style

Chipi, E.; Salvadori, N.; Farotti, L.; Parnetti, L. Biomarker-Based Signature of Alzheimer’s Disease in Pre-MCI Individuals. Brain Sci. 2019, 9, 213.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop